These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 26964482

  • 21. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
    Pranatharthiharan S, Patel MD, Malshe VC, Pujari V, Gorakshakar A, Madkaikar M, Ghosh K, Devarajan PV.
    Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
    [Abstract] [Full Text] [Related]

  • 22. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H, Yu Z, Liu Y, Yuan W, Yang T, You J, He X, Lee RJ, Li L, Xu C.
    Int J Nanomedicine; 2017 Nov; 12():5271-5287. PubMed ID: 28769563
    [Abstract] [Full Text] [Related]

  • 23. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
    Dai Y, Xing H, Song F, Yang Y, Qiu Z, Lu X, Liu Q, Ren S, Chen X, Li N.
    J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma.
    Yin X, Xiao Y, Han L, Zhang B, Wang T, Su Z, Zhang N.
    AAPS PharmSciTech; 2018 Jul; 19(5):2133-2143. PubMed ID: 29714002
    [Abstract] [Full Text] [Related]

  • 27. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY, Lin TsT, Sung YC, Liu YC, Chiang WH, Chang CC, Liu JY, Chen Y.
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [Abstract] [Full Text] [Related]

  • 28. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
    Wang J, Wu Z, Pan G, Ni J, Xie F, Jiang B, Wei L, Gao J, Zhou W.
    Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
    [Abstract] [Full Text] [Related]

  • 29. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
    Guo H, Lai Q, Wang W, Wu Y, Zhang C, Liu Y, Yuan Z.
    Int J Pharm; 2013 Jul 15; 451(1-2):1-11. PubMed ID: 23618965
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. In vivo pharmacokinetics, biodistribution and the anti-tumor effect of cyclic RGD-modified doxorubicin-loaded polymers in tumor-bearing mice.
    Wang C, Li Y, Chen B, Zou M.
    Colloids Surf B Biointerfaces; 2016 Oct 01; 146():31-8. PubMed ID: 27244048
    [Abstract] [Full Text] [Related]

  • 36. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
    Zheng G, Zhao R, Xu A, Shen Z, Chen X, Shao J.
    Eur J Pharm Sci; 2018 Jan 01; 111():492-502. PubMed ID: 29107835
    [Abstract] [Full Text] [Related]

  • 37. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound.
    Deng Z, Xiao Y, Pan M, Li F, Duan W, Meng L, Liu X, Yan F, Zheng H.
    J Control Release; 2016 Dec 10; 243():333-341. PubMed ID: 27984104
    [Abstract] [Full Text] [Related]

  • 38. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J.
    J Hepatol; 2016 May 10; 64(5):1090-1098. PubMed ID: 26809111
    [Abstract] [Full Text] [Related]

  • 39. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
    Grillone A, Riva ER, Mondini A, Forte C, Calucci L, Innocenti C, de Julian Fernandez C, Cappello V, Gemmi M, Moscato S, Ronca F, Sacco R, Mattoli V, Ciofani G.
    Adv Healthc Mater; 2015 Aug 05; 4(11):1681-90. PubMed ID: 26039933
    [Abstract] [Full Text] [Related]

  • 40. Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer.
    Chang JE, Yoon IS, Sun PL, Yi E, Jheon S, Shim CK.
    J Photochem Photobiol B; 2014 Nov 05; 140():49-56. PubMed ID: 25090224
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.